Analysis Of The Weekly Performance Of Immunovant Inc. (IMVT)


Immunovant Inc. (NASDAQ:IMVT) finished Friday with an addition of $0.34 to close at $17.75, an upside of 1.95 percent. An average of 864,500 shares of common stock have been traded in the last five days. There was a gain of $1.10 in the past week, and it reached a new high 24 times over the past 12 months. The last 20 days have seen an average of 1,185,400 shares traded, while the 50-day average volume stands at 1,058,448.

IMVT stock has increased by 35.39% in the last month. The company shares reached their 1-month lowest point of $13.10 on 12/01/22. With the stock rallying to its 52-week high on 12/29/22, shares of the company touched a low of $3.14 and a high of $17.90 in 52 weeks. It has reached a new high 25 times so far this year and achieved 108.33% or $9.23 in price. In spite of this, the price is down -0.84% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

IMVT stock investors should be aware that Immunovant Inc. (IMVT) stock had its last reported insider trading activity 71 days ago on Oct 21. In this transaction, the insider spent $3,297. Chief Dev. & Tech. Officer, Butchko Julia G., disposed of 928 shares at a price of $9.18 on Oct 13. The insider now owns more than $8,519 worth of shares. Prior to that, Chief Executive Officer Salzmann Peter went on to Sale 2,793 shares at $9.18 each on Oct 13. An amount of $25,640 was transacted.

Valuation Metrics

Immunovant Inc. (IMVT) stock’s beta is 1.12. Other valuation ratios to consider include the price-to-book (PB) ratio at 5.24.

Financial Health

The quick ratio of Immunovant Inc. for the three months ended June 29 was 13.40, and the current ratio was 13.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Immunovant Inc.’s return on assets was -36.40%.

Earnings Surprise

The analyst consensus anticipated Immunovant Inc.’s latest quarter earnings to come in at -$0.4 per share, but it turned out to be -$0.35, a 12.50% surprise. For the quarter, EBITDA amounted to -$49.57 million. Shareholders own equity worth $129.18 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Immunovant Inc. (IMVT) price momentum. RSI 9-day as of the close on 30 December was 78.60%, suggesting the stock is Overbought, with historical volatility in this time frame at 41.86%.

As of today, IMVT’s price is $17.17 +6.61% or $1.10 from its 5-day moving average. IMVT is currently trading +27.97% higher than its 20-day SMA and +243.99% higher than its 100-day SMA. However, the stock’s current price level is +92.10% above the SMA50 and +205.51% above the SMA200.

The stochastic %K and %D were 91.36% and 87.82%, respectively, and the average true range (ATR) was 0.78. With the 14-day stochastic at 95.71% and the average true range at 0.78, the RSI (14) stands at 75.74%. The stock has reached 0.73 on the 9-day MACD Oscillator while the 14-day reading was at 1.31.

Analyst Ratings

UBS downgraded Immunovant Inc. (NASDAQ: IMVT) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Immunovant Inc. (IMVT) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell IMVT, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.

What is IMVT’s price target for the next 12 months?

Analysts predict a range of price targets between $4.00 and $30.00, with a median target of $15.50. Taking a look at these predictions, the average price target given by analysts for Immunovant Inc. (IMVT) stock is $16.13.


Please enter your comment!
Please enter your name here